Skip to content

Individually Tailored and Integrated Social Support Network for Tobacco Cessation

Live Inspired: Individually Tailored and Integrated Social Support Network for Tobacco Cessation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03152253
Enrollment
284
Registered
2017-05-12
Start date
2017-05-30
Completion date
2018-11-30
Last updated
2019-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Keywords

Tobacco, Smoking, Text Message

Brief summary

This study will continue development of a quit smoking program delivered through text messaging. Upon completion of programming we will enroll 280 participants and randomize them to a control condition or the intervention condition. Assessments will occur at enrollment, and both 3 and 6 month follow ups.

Detailed description

This study builds on pilot work in which Live Inspired LLC and research partners developed T2Q (formerly Text-2-Quit) a smoking cessation intervention delivered through text messaging. T2Q is a unique program with a number of features that provide superior support and service compared to existing text message quit smoking products. T2Q is 100% accessible through text messaging provides medication support for quitting smoking, an integrated social support network and live counseling. This phase II project will add functionality to accommodate use of multiple forms of quit smoking medications, and then conduct a rigorous test of the efficacy of T2Q among 280 adult smokers and examine smoking outcomes compared to controls at 3 and 6 months follow up. The study will also examine changes in smoking-related attitudes and behaviors among T2Q users to identify strengths and any potential weaknesses that may affect T2Q's impact on smoking outcomes. Analyses will examine the quality of social interactions within the T2Q integrated social support network and their role in promoting smoking abstinence. We will also conduct interviews with study participants in the T2Q arm to enable understanding of the user's experience with T2Q. Results of this trial will demonstrate the efficacy of T2Q - providing important credibility needed for successful commercialization. This research will also provide important data for possible enhancements to improve consumer appeal prior to commercialization. This proposal finalizes development and testing of a unique, highly scalable intervention that can reach a U.S. market comprised of over 34 million adult smokers who use text messaging, and provide them with effective, evidence-based treatment. Text messaging enjoys near-market saturation and is a widely preferred method of communication with deep penetration across diverse groups. Wide availability of an attractive and effective smoking cessation program such as T2Q, may exert a powerful, sustained impact on public health

Interventions

BEHAVIORALText My Quit (TMQ)

Text messages designed to aid smoking cessation

BEHAVIORALPeer Support

A group chat room for peer support

Generic motivational messages not related to smoking cessation

Sponsors

Live Inspired, LLC
CollaboratorINDUSTRY
The Miriam Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age \>18 * current daily cigarette smoker * use of text messaging at least once per week * interested in quitting smoking within the next 30 days * has access to a physician or healthcare provider * no current drug/alcohol abuse.

Exclusion criteria

* Non-English Speaking * Currently using quit-smoking medications or therapies

Design outcomes

Primary

MeasureTime frameDescription
Smoking Abstinence6 month follow upSelf-report of no smoking for the past 7 days

Secondary

MeasureTime frameDescription
Social support network use12 weeksnumber of messages sent to the chat room

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026